BeyondSpring (BYSI) Stock Price, News & Analysis

Company Overview

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a selective immunomodulating microtubule-destabilizing agent designed to stimulate the immune system while affecting tumor-cell biology.

BeyondSpring has evaluated plinabulin for the prevention of chemotherapy-induced neutropenia, a potentially serious complication of cancer treatment, and for use in combination with other therapies in oncology, including treatment approaches for non-small cell lung cancer. The candidate has been studied in late-stage clinical development, although regulatory and development outcomes may vary by indication and jurisdiction.

Founded in 2010, BeyondSpring has pursued a global drug-development strategy with clinical and regulatory activities involving the United States, China and other international markets. The company was co-founded and is led by Lan Huang, Ph.D., who has served as its chief executive officer and has been associated with the company’s research and development programs.

Key Stats

• Today's Range: $0.78 to $0.85
• 50-Day Range: $0.60 to $1.19
• 52-Week Range: $0.57 to $2.44
• Volume: 68,954 shs
• Average Volume: 613,088 shs
• Market Capitalization: $32.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BeyondSpring Stock Analysis - MarketRank™

BeyondSpring scored higher than 3% of companies evaluated by MarketBeat, and ranked 873rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BeyondSpring has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BeyondSpring has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BeyondSpring is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeyondSpring is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.86% of the float of BeyondSpring has been sold short.

Short Interest Ratio / Days to Cover

BeyondSpring has a short interest ratio ("days to cover") of 18.74, which indicates bearish sentiment.

Change versus previous month

Short interest in BeyondSpring has recently decreased by 0.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeyondSpring does not currently pay a dividend.

Dividend Growth

BeyondSpring does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.17

News Sentiment

BeyondSpring has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for BeyondSpring this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BeyondSpring insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.31% of the stock of BeyondSpring is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.29% of the stock of BeyondSpring is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BYSI
• CIK: 1677940
• Web: www.beyondspringpharma.com
• Phone: (646) 528-4184
• Fax: 1-646-882-4228
• Employees: 44
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -28.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.70
• Quick Ratio: 0.70

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 18.50
• Cash Flow: $0.11 per share
• Price / Cash Flow: 6.93
• Book Value: ($0.59) per share
• Price / Book: -1.33

Miscellaneous

• Outstanding Shares: 41,120,000
• Free Float: 29,068,000
• Market Cap: $32.37 million
• Optionable: Optionable
• Beta: -0.21